<DOC>
	<DOCNO>NCT03090854</DOCNO>
	<brief_summary>Several previous study assess acetylcholine ( Ach ) acetylcholinesterase activity ( AchE-a ) level Alzheimer 's disease ( AD ) pathophysiology . The cerebrospinal fluid ( CSF ) Ach level significantly decrease AD patient , correlate positively dementia score MMSE ( 1 , 2 ) . Two study demonstrate positive correlation CSF AchE-a CSF Tau , phosphorylated-Tau ( P-Tau ) AB 1-42 peptide ( 3,4 ) . ChEIs ( cholinesterase inhibitor ) approve treatment AD 20 30 % patient responder ( 5 ) . Any consistent data allow clinician predict response treatment . The link basal cholinergic status ChEIs efficiency never do . Even , wild research AD treatment , ChEIs treatment act Ach pathway remain long time valuable treatment particularly moderate AD disease modify therapy show efficiency . The investigator 's objective prospectively explore predict value CSF Ach AchE-a level ChEIs response AD patient .</brief_summary>
	<brief_title>Cholinergic Markers Alzheimer 's Disease</brief_title>
	<detailed_description>Strategy : Within framework usual management , investigator propose protocol patient assay CSF biomarkers CSF AD biological profile introduction IChEs accept Their CSF stock biobank . Patients additional neuropsychological assessment . The rest care come current care . The quantification ACh CSF perform tandem mass spectrometry separation liquid chromatography ( LC-MS / MS ) . AChE activity determine colorimetric determination . The investigator 's objective prospectively explore predict value CSF Ach AchE-a level ChEIs response AD patient . The evaluation criterion - Difference mean value ACh level AChE activity CSF responder non-respondier group patient . - `` Responder '' patient define improvement least 4 point ADAS-Cog ( cognitive part ) ADAS-Cog 6 month treatment . - `` Non-responders '' define aggravation , lack improvement improvement &lt; 4 point ADAS-Cog scale .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinergic Agents</mesh_term>
	<criteria>Inclusion criterion : Male Female age ≥ 50 year Patients biological profile CSF biomarkers favor Alzheimer 's disease Alzheimer 's disease diagnose accord McKahnn 2011 criterion [ 1 ] mild moderate stage Clinical Dementia Rating ( CDR ) ≤2 Indication treatment inhibitor acetycholinesterase Patients benefit national health coverage Patients subject legal protection Fluent French language Exclusion criterion : No indication contraindication PL Contraindications IChEs Patient include antiAlzheimer drug clinical trial Clinical Dementia Rating CDR &gt; 2 Another cause neurocognitive decline Serious psychiatric disorder Other serious lifethreatening condition</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Cognition</keyword>
	<keyword>Cholinergic target</keyword>
</DOC>